Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Therapeutic Effect of Chemotherapy Azacytidine Plus CAOLD Regimen on Patients With Relapsed/Refractory Peripheral T-Cell Lymphomas

NCT06176027 is registered in ClinicalTrials.gov with Navy General Hospital, Beijing as lead sponsor.

NCT NCT06176027
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06176027 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Therapeutic Effect of Chemotherapy Azacytidine Plus CAOLD Regimen on Patients With Relapsed/Refractory Peripheral T-Cell Lymphomas
Lead sponsor
Navy General Hospital, Beijing
Phase
Phase 1/2
Overall status
Recruiting
Start date
October 1, 2024
Completion date
September 1, 2030
Enrollment
52 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

refractory peripheral t-cell lymphomas, relapsed peripheral t-cell lymphomas